P2Y12抑制剂与癌症风险的相关性研究进展

Studies on Correlation Between P2Y12 Inhibitors and Cancer Risk

以氯吡格雷、替格瑞洛为代表的P2Y12抑制剂目前被广泛应用于心脑血管疾病的抗血小板治疗,而血小板功能的变化可能影响肿瘤的发生发展,因此P2Y12抑制剂的应用与癌症发生风险的相关性备受关注.目前的证据显示应用P2Y12抑制剂总体安全,一般不会升高患者的癌症风险,相反甚至可能降低癌症发生率.基础研究表明,P2Y12抑制剂可能通过影响血小板功能、上皮细胞-间充质转化、炎症免疫因子、肿瘤内血管新生以及血小板-肿瘤细胞相互作用等多种机制抑制肿瘤细胞的增殖和迁移.

P2Y12 inhibitors,such as clopidogrel and ticagrelor,are widely used in antiplatelet therapy for cardiovascular and cerebrovascular diseases,and the changes of platelet function may affect the development and progression of tumor,so the correlation between P2Y12 inhibitors and cancer risk has attracted much attention.According to the literature review,current evidence shows that P2Y12 inhibitors are generally safe,without increasing the risk of cancer.On the contrary,they may even reduce the incidence of cancer.Basic researches show that P2Y12 inhibitors may inhibit the proliferation and migration of tumor cells by influencing platelet function,epithelial-mesenchymal transition,inflammatory and immunoregulatory factors,tumor angiogenesis and platelet-tumor cell interaction.